AbbVie Inc. is 104.2x more valuable than CATALYST PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $3.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CPRX | ABBV |
|---|---|---|
| Market cap | $3.84 B | $399.47 B |
| US-listed rank | #1606 | #28 |
| Revenue (latest FY) | $588.99M | $61.16B |
| Net income (latest FY) | $214.33M | $4.23B |
| Net margin | 36.4% | 6.9% |
| P/E (trailing FY) | 17.9 | 94.5 |
| SEC filings | 1,337 | 1,008 |
AbbVie Inc. is 104.2x more valuable than CATALYST PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $3.84 B).
In their latest fiscal years, CATALYST PHARMACEUTICALS, INC. reported $588.99M in revenue while AbbVie Inc. reported $61.16B.
Full pages: CATALYST PHARMACEUTICALS, INC. and AbbVie Inc., or browse the full rankings.